Do MTHFD1 rs2236225 and BHMT rs3733890 variants increase vulnerability to methylation stress when B12 or folate intake is marginal?

The regulation of homocysteine and the maintenance of cellular methylation rely on the efficient cycling of one-carbon units through two primary pathways: the folate/B12-dependent cycle and the betaine-dependent backup pathway. Genetic variants in the MTHFD1 and BHMT genes can impair these pathways, creating a state of metabolic vulnerability.

Clinical and effectiveness evidence

The MTHFD1 rs2236225 (G1958A) and BHMT rs3733890 (G742A) variants have measurable impacts on one-carbon metabolism, particularly when nutritional status is suboptimal:

• MTHFD1 rs2236225: This variant is associated with lower serum folate levels and altered choline metabolism. Under conditions of folate restriction, carriers show a decreased ability to maintain the one-carbon pool required for DNA synthesis and methylation.
• BHMT rs3733890: Carriers of the A-allele exhibit a significantly higher risk (OR 2.8 in specific stressed populations) of elevated homocysteine and are more likely to experience "treatment failure" when attempting to lower homocysteine with folate alone. This suggests the backup pathway is less effective at compensating for primary cycle deficiencies.
• Nutrient Interaction: Research indicates that when vitamin B12 or folate levels are marginal, the body shifts its reliance toward the BHMT-mediated pathway. If this backup pathway is also genetically impaired by the rs3733890 variant, the risk of hyperhomocysteinemia and "methylation stress" increases.

Mechanistic explanations

The biological impact of these variants stems from specific enzymatic impairments:

• MTHFD1 Enzymatic Shift: The rs2236225 variant causes an R653Q amino acid substitution that specifically impairs the formyltetrahydrofolate synthetase domain. This reduces the conversion of formate into 10-formyl-THF, limiting the availability of methyl groups for the entire cytoplasmic folate cycle.
• BHMT Substrate Affinity: The rs3733890 variant alters the BHMT enzyme's kinetic properties (Km values), reducing its affinity for substrates. Because BHMT is responsible for approximately 50% of homocysteine remethylation in the liver, this reduction directly limits the capacity to recycle homocysteine into methionine via the betaine-dependent route.
• Pathway Convergence: MTHFD1 provides the 5,10-methylene-THF necessary for the primary B12-dependent remethylation arm. When this arm is hindered by low B12/folate or the MTHFD1 variant, the BHMT pathway must compensate. Having variants in both genes simultaneously weakens both the primary and backup mechanisms for maintaining methylation balance.

Bottom line

The MTHFD1 rs2236225 and BHMT rs3733890 variants reduce the efficiency of the primary and backup homocysteine remethylation pathways, respectively. While these effects may be manageable with optimal nutrition, they significantly increase vulnerability to elevated homocysteine and impaired methylation when B12 or folate intake is marginal.